VP-001 has the hallmarks of being a most wonderfully designed drug
the early pre-clinical efficacy results were stunning, and the final cap-stone in safety doubles down on the above statement
It’s important to note that drug design, conception and lead formulation remains the engine room of value for us, and hopefully this will spark renewed interest as to the strength of PYC’s core capabilities (ie individual Lead values vs platform values in furnishing such leads)
Ann: Successful Toxicology Results Pave Way for Phase 2 Trial, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
-0.025(1.89%) |
Mkt cap ! $755.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.32 | $1.30 | $478.1K | 365.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |